Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Genenta Science SpA Sponsored ADR ( (GNTA) ) has provided an announcement.
Genenta Science S.p.A. reported its financial results for the six months ended June 30, 2025, revealing a net loss of €3.83 million, compared to a €4.04 million loss in the same period in 2024. Despite the reduced losses, the company’s financial position showed an increase in total assets to €21.55 million from €14.82 million at the end of 2024, indicating a strengthening balance sheet. The financial results highlight ongoing challenges in managing operational expenses while also reflecting improvements in asset management, which could impact future strategic decisions and stakeholder confidence.
The most recent analyst rating on (GNTA) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Genenta Science SpA Sponsored ADR stock, see the GNTA Stock Forecast page.
More about Genenta Science SpA Sponsored ADR
Genenta Science S.p.A. operates in the biotechnology industry, focusing on the development of innovative gene therapies for cancer treatment. The company is based in Milan, Italy, and is engaged in advancing its proprietary platform to target tumor microenvironments.
Average Trading Volume: 9,062
Technical Sentiment Signal: Sell
Current Market Cap: $59.99M
For detailed information about GNTA stock, go to TipRanks’ Stock Analysis page.